The antiproliferative and antimetastatic compound L651582 inhibits muscarinic acetylcholine receptor-stimulated calcium influx and arachidonic acid release
- PMID: 1646332
The antiproliferative and antimetastatic compound L651582 inhibits muscarinic acetylcholine receptor-stimulated calcium influx and arachidonic acid release
Abstract
L651582, a carboxyamide-amino-imidazole, was shown previously to have antiproliferative and antimetastatic properties at low micromolar concentrations; yet little is known about its cellular mechanism(s) of action. L651582 was tested for its ability to block receptor-stimulated calcium influx, arachidonic acid release, inositol phosphate and cyclic AMP (cAMP) generation. These signal transduction pathways are activated by muscarinic receptors transfected and expressed in Chinese hamster ovary cells. L651582 blocked muscarinic m5 receptor-stimulated 45Ca++ influx and release of arachidonic acid at low micromolar concentrations. Muscarinic receptor-stimulated release of arachidonic acid was shown previously to be dependent on calcium influx and not intracellular calcium release suggesting L651582 may be useful as calcium channel blocker. At low micromolar concentrations, L651582 had little effect on muscarinic m5 receptor-stimulated release of inositol phosphates or cAMP accumulation. Moreover, L651582 had little effect on muscarinic m2 receptor-mediated inhibition of forskolin-stimulated cAMP accumulation. Above 10 microM, L651582 inhibited all second messenger pathways tested and inhibited cell growth, suggesting its action may be less specific and toxic at these concentrations.
Similar articles
-
Structure-function analysis of signal and growth inhibition by carboxyamido-triazole, CAI.Cancer Res. 1994 Feb 15;54(4):935-42. Cancer Res. 1994. PMID: 8313384
-
A transfected m5 muscarinic acetylcholine receptor stimulates phospholipase A2 by inducing both calcium influx and activation of protein kinase C.J Pharmacol Exp Ther. 1990 Dec;255(3):1140-7. J Pharmacol Exp Ther. 1990. PMID: 2124620
-
In vivo efficacy of a novel inhibitor of selected signal transduction pathways including calcium, arachidonate, and inositol phosphates.Cancer Res. 1992 Jun 1;52(11):3208-12. Cancer Res. 1992. PMID: 1591730
-
Muscarinic acetylcholine receptor subtypes associated with release of Alzheimer amyloid precursor derivatives activate multiple signal transduction pathways.Ann N Y Acad Sci. 1993 Sep 24;695:15-8. doi: 10.1111/j.1749-6632.1993.tb23020.x. Ann N Y Acad Sci. 1993. PMID: 8239275 Review.
-
Muscarinic receptor subtypes: inositol phosphates and intracellular calcium.Biochem Soc Trans. 1992 Feb;20(1):130-5. doi: 10.1042/bst0200130. Biochem Soc Trans. 1992. PMID: 1633938 Review. No abstract available.
Cited by
-
Mechanisms of integrin-mediated calcium signaling in MDCK cells: regulation of adhesion by IP3- and store-independent calcium influx.Mol Biol Cell. 1996 Jul;7(7):1025-41. doi: 10.1091/mbc.7.7.1025. Mol Biol Cell. 1996. PMID: 8862518 Free PMC article.
-
CAI: effects on cytotoxic therapies in vitro and in vivo.Cancer Chemother Pharmacol. 1994;34(6):515-21. doi: 10.1007/BF00685664. Cancer Chemother Pharmacol. 1994. PMID: 7923563
-
Calcium-mediated signal transduction: biology, biochemistry, and therapy.Cancer Metastasis Rev. 1994 Mar;13(1):31-44. doi: 10.1007/BF00690417. Cancer Metastasis Rev. 1994. PMID: 8143344 Review.
-
A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors.Cancer Biol Ther. 2009 Oct;8(19):1800-5. doi: 10.4161/cbt.8.19.9593. Cancer Biol Ther. 2009. PMID: 19738417 Free PMC article. Clinical Trial.
-
Aberrant signaling pathways in meningiomas.J Neurooncol. 2010 Sep;99(3):315-24. doi: 10.1007/s11060-010-0381-8. Epub 2010 Sep 14. J Neurooncol. 2010. PMID: 20838852 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
